CompletedNCT00322764
Uridine for depression in bipolarity type I
About this title
Read the official source — NCT00322764Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Stanford and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 80
- Sponsor
- Repligen Corporation
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00322764
- Official title
Show the full official title
Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stanford · Smyrna · Indianapolis
8 more locations
- Rockville
- Boston
- New York
- Cincinnati
- Cleveland
- Austin
- Dallas
- San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Repligen Corporation.
Did this study involve medication?
Yes. The study involved medication, including Uridine.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
